Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Triclabendazole · Egaten, EGA230B

Small molecule · developed by Novartis

Approved FDA, Feb 2019
NVS Developer

What is Triclabendazole?

Triclabendazole is an anthelmintic agent against Fasciola species, given as an oral tablet. It is used in the treatment of fascioliasis, a parasitic infection of the liver caused by liver flukes.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
Egaten, EGA230B, NSC-759250
Drug type
Small molecule
Therapy area
Infectious disease
Developer
Novartis (NVS)
FDA status
Approved as Egaten (February 13, 2019), NDA208711 · FDA label
UNII
4784C8E03O

✅ FDA-approved uses

From the indications section of the FDA label (version of Jun 4, 2026). Read the full label for the exact wording, limitations and safety information.

Conditions studied

Fascioliasis

More from Novartis

Sources

Updated Nov 8, 2026. Something wrong or missing? Report it on the NVS page.

Follow NVS, the company behind Triclabendazole

See NVS's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

NVS catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.